Overview

Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patients

Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to investigate whether Florbetaben (BAY94-9172)positron emission tomography (PET) is able to distinguish between subjects with mild cognitive impairment (MCI) progressing to Alzheimer's disease (AD) from those with MCI not progressing to AD.
Phase:
Phase 1
Details
Lead Sponsor:
Life Molecular Imaging SA
Piramal Imaging SA